MoneyWorks4Me

Gufic Biosciences gets nod from NMPA for PRILOCAINE API

17 Jun 2023 Evaluate

Gufic Biosciences (Gufic) has received approval from National Medical Products Administration (NMPA), China for its product PRILOCAINE (API) which is an amide-type local anaesthetic of fast onset and intermediate duration of action. This approval shall help commercialization of the said product in China and explore Chinese market. 

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..